Citations

Showing 10 of 108152 citations.

Molecular Mechanisms Involved in Homing and Migration of Plasma Cells in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway.
Kimlinger, Terry, Timm, Michael, Kumar, Ashock, Ghobrial, Irene M. , Ghobrial, Joanna M. , Bramati, Patricia S. , Hedin, Karen E. , Witzig, Thomas E.

Mayo Clinic

Blood | October 12, 2019 | Volume: 104 | Issue: 11 | Pages: 2188-2188

10.1182/blood.v104.11.2188.2188 Get It

Abstract Malignant plasma cells characteristically home to the bone marrow (BM). However, the mechanisms by which cells are recruited into and mobilized from the bone marrow into the peripheral blood (PB) are not well understood. In this study, we explore the molecular mechanisms involved in homing and migration of plasma cells in response to CXCR4 and investigated the role of the PI3K pathway in migration of MM cells in response to SDF-1. CXCR4 surface expression was determined by FACS analysis (PE CXCR4, Pharmingen) using samples from bone marrow and peripheral blood of patients diagnosed with multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS) and primary systemic amyloidosis (AL). All results were expressed as percent expression in gated CD38+ and CD45+ cells. Boyden chamber in vitro migration assays were performed using Kas6/1MM cells. In addition, live confocal microscopy was used to visualize changes in the subcellular location of YFP-fluorescent CXCR4 before and after SDF-1 stimulation. Cells were pretreated with 10mM LY294002 or 200nM rapamycin to assess the effect of inhibition of PI3K or mTOR on CXCR4 subcellular localization. Immunoblotting was performed to confirm inhibition of the PI3K pathway. Comparisons between groups was performed using Mann-Whitney testing. The median CXCR4 expression is described in table 1. There was a significant difference between expression of BM CXCR4 in MM and MGUS (p=0.02). SDF-1 induced dose dependent migration of Kas 6/1 cells indicating a functional CXCR4 receptor. MM cells transfected with YFP-CXCR4 demonstrated surface localization on the cells. 3-Dimensional and continuous live imaging after SDF-1 stimulation for 30 minutes demonstrated alterations in the CXCR4-YFP leading to its capping, internalization subcellularly, and production of pseudopodia in response to SDF-1. This process was abrogated with pretreatment with LY294002 and rapamycin. These data demonstrate for the first time that the surface expression of CXCR4 is markedly elevated in the peripheral blood as compared to the bone marrow. Once in the bone marrow, and with the presence of excess SDF-1, the receptor becomes internalized and downregulated. In contrast to MM, CXCR4 expression on plasma cells in the bone marrow of normal and MGUS patients was higher. In addition, we demonstrate that the process of CXCR4 subcellular localization is abrogated by the administration of PI3K inhibitors LY294002 and rapamycin. These data suggest that CXCR4 expression is required for MM cells to circulate, and that downregulation occurs in the BM leading to immobilization of the cells. Future clinical trials using CXCR4 inhibitors, or inhibitors of PI3K and mTOR to prevent the homing and migration of MM cells into the bone marrow may be explored. This was supported in part by CAP50 CA97274. CXCR4 expression N=45 Median CXCR4% expression of total plasma cells Range MM BM (n=23) 27 4.3–90.1 MM PB (n=5) 91 60–95.5 MGUS BM (n=6) 65 41–78.6 AL BM (n=7) 46 17.5–71.6 Normal BM (n=4) 59 6.3–69.5 Kas6/1 cell line 100 -
Autologous Hemopoietic Stem Cell Transplantation Is a Viable Treatment Option for Post Liver Transplant Lymphoproliferative Disorder: A Case Report.
Amar, Surabhi, Sekhon, Sudhir Singh, Roy, Vivek

Mayo Clinic

Blood | October 12, 2019 | Volume: 108 | Issue: 11 | Pages: 5447-5447

10.1182/blood.v108.11.5447.5447 Get It

Post-transplant lymphoproliferative disorders (PTLD) are B-cell disorders characterized by abnormal lymphoid proliferation due to immunesuppression mediated T-cell dysfunction after organ transplantation, and carry a poor prognosis. Reduction of immunesuppression is the first line of therapy but involves the risk of allograft rejection. Anti-viral agents like acyclovir, intravenous immunoglobulin, interferon-α, anti interleukin -6 antibodies, chemotherapy and rituximab are other treatments that have been tried with limited success. EBV-specific adaptive immunetherapy is promising but only available in a few centers. Prognosis is poorer in patients with relapsed disease. We report the case of a 46 year-old liver transplant recipient, with recurrent PTLD after liver transplantation, who was successfully treated with high dose chemotherapy followed by autologous bone marrow transplant (ABMT). He had undergone an orthotopic liver transplant (OLT) 13 years ago for primary sclerosing cholangitis. PTLD (EBV related, Hodgkin like, CD20+ and CD30+) developed 7 years ago, and initially resolved with ganciclovir and reduction of immunesuppression. The patient relapsed 5 years later. Immunesuppression was discontinued and 3 cycles of rituximab with CHOP (R-CHOP) followed by 4 doses of R at weekly intervals were given leading to complete response. Four months later, he again relapsed and responded to 4 more cycles of R-CHOP. He was referred to our center for transplant evaluation. Progenitor cell mobilization with filgrastim was unsuccessful. He underwent an unstimulated bone marrow harvest yielding 1.02 × 10 6 CD34 cells/kg. Transplant conditioning was with R-BEAM. Because of abnormal liver function tests and concern for further hepatotoxicity, carmustine dose was reduced by 50%. Immunesuppression for OLT was withheld during the transplant period. He tolerated the chemotherapy well but had delayed neutrophil and platelet engrafment (days +31 and +50 respectively). Liver functions deteriorated in the post transplant period, but responded to reinitiation of prednisone and tacrolimus on days +41 and +50, respectively. Post transplant PET/CT imaging performed on day+45 revealed complete resolution of his lymphadenopathy. He continues to be asymptomatic with no evidence of relapse days+ 72 after transplant, at the time of this writing. ABMT is the standard of care for chemotherapy-sensitive relapsed lymphomas. However, the complexity of ABMT after a prior solid organ transplant limits its use for relapsed PTLD. There is a higher likelihood of regimen-related toxicity, and immunesuppression needs to be carefully managed. While it is desirable to reduce immunesuppression during the transplant period to minimize infections and to control PTLD, this has to be balanced against the risk of solid organ graft rejection. This is particularly critical in patients with liver transplantation in whom (unlike renal graft) loss of liver graft may be fatal. There are only 6 previous cases of PTLD treated with stem cell transplant, but none of these patients had a prior OLT. Our experience with this case suggests that autologous bone marrow transplant can be a potential treatment option for patients with recurrent PTLD in selected patients. Appropriate dose modification of conditioning regimen and careful management of peritransplant immunesuppression appears important for successful outcome.
Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.
Tracy, Jeannette L., Gorre, M., Griffin, James D. , Beran, Miloslav, Sausville, Edward A., Chandra, Joya , Talpaz, Moshe , Verstovšek, Srđan , Sawyers, Charles L. , Kaufmann, Scott H.

Mayo Clinic

Blood | October 12, 2019 | Volume: 104 | Issue: 11 | Pages: 2097-2097

10.1182/blood.v104.11.2097.2097 Get It

Abstract The impetus for kinase inhibition as a therapeutic endpoint in leukemia research has been driven largely by the success of imatinib mesylate in chronic myelogenous leukemia. However, while imatinib mesylate has been extremely effective in the treatment of chronic phase CML, resistant disease often emerges in both Philadelphia positive ALL and aggressive phase CML patients. Adaphostin is a tyrphostin inhibitor originally developed to target the bcr/abl kinase and demonstrates selectivity in CML patient isolates. Here we show that in vitro, adaphostin is cytotoxic in numerous models that are resistant to imatinib. Features of adaphostin action in bcr/abl containing cells include apoptosis induction via an oxidant dependent mechanism and degradation of bcr/abl protein. Cell lines containing point mutations in p210 bcr/abl which confer imatinib resistance exhibit intracellular peroxide production and DNA fragmentation in response to adaphostin. Bcr/abl degradation also occurs but can be dissociated from peroxide production and subsequent apoptosis signaling. Similar data has also been obtained in cell lines containing p190 bcr/abl. Studies extending these observations into mononuclear and polymorphonuclear cells from imatinib resistant CML patients and Ph+ ALL patients confirm the same mechanism in primary clinical isolates. Collectively, these data suggest that reactive oxygen species generation by adaphostin bypasses imatinib resistance in CML and Ph+ ALL. Further studies dissecting the mechanism of ROS generation by adaphostin in imatinib resistant cells may lead to the identification of new therapeutic targets.
ATM Gene Point Mutation and Frameshift Mutation Are Found In High-Risk, Untreated Chronic Lymphocytic Leukemia Patients with Interstitial Deletion of Chromosome 11q and Uniparental Disomy of Chromosome 11q
Schichman, Steven A., Saldivar, Juan‐Sebastian, Stone, Annjanette , Winters, Maria, Carter, Weleetka , Frederick, Lori, Viswanatha, David S., Schichman, Steven A. , Han, Jennifer , Zent, Clive S.

Mayo Clinic

Blood | October 12, 2019 | Volume: 116 | Issue: 21 | Pages: 2420-2420

10.1182/blood.v116.21.2420.2420 Get It

Abstract Abstract 2420 Introduction: Interstitial deletion of chromosome 11q (11q-) detected by fluorescence in situ hybridization (FISH) is an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL). CLL patients with 11q- often have younger age of onset, bulky lymphadenopathy, and poorer overall survival. The ataxia-telangiectasia mutated (ATM) gene, which encodes a protein kinase central to DNA damage response, is thought to be the critical gene in CLL 11q- through loss of ATM function. A subgroup of CLL patients with 11q- has been shown by other investigators to have a mutation in the remaining ATM allele, supporting a loss-of-function hypothesis. In an ongoing study, we are using SNP-based whole genome copy number variation (CNV) analysis to characterize in detail the 11q deletions in CLL patients. In addition, we have reported uniparental disomy (UPD) of 11q in CLL patients negative for FISH abnormalities. Here we report direct DNA sequence analysis of the ATM gene in CLL patients with 11q- and with UPD of 11q. Patients and Methods: We performed CNV analysis and ATM sequencing on 10 patients aged 29–67 with early-intermediate stage, untreated CLL who had high risk for disease progression based on molecular and immunophenotypic markers. Eight patients had 11q- and 2 patients had UPD of 11q. CLL cells and normal cells were separated from patient peripheral blood samples by immunomagnetic beads. CNV analysis was performed on purified genomic DNA from CLL and normal cells for each patient to distinguish acquired copy number changes in malignant cells from polymorphic CNVs in the human genome. We used the Illumina 660w-quad beadchip, a SNP-based microarray for CNV analysis. CNV data was analyzed by CNV partition and PennCNV software. DNA sequence analysis of the ATM gene was performed by the dideoxy chain termination method using an ABI 3730 DNA Analyzer. All coding regions of the ATM gene (exons 4–65) and associated splice site junctions were amplified by PCR using purified genomic DNA from CLL cells. DNA sequence of the PCR products was determined on both strands. Sequence data was analyzed by Sequencher software. Results: In the 8 CLL patients with 11q−, CNV analysis demonstrates hemizygous interstitial deletions that vary from 980 Kb to 43.2 Mb. All deletions include the region of the ATM gene at 11q22.3. Two out of these 8 patients have a mutation in the residual ATM allele. One patient (CLL010) has a point mutation in exon 61 of ATM (c.8600G>A (gly2867glu)) that likely involves the substrate-binding region of the PI3-kinase domain. One patient (CLL029) has a frameshift mutation in exon 12 of ATM (c.1401_1405delCAAGA; asp467fs) that causes a premature stop signal at codon 484, presumably resulting in a truncated protein. In the 2 CLL patients with UPD of 11q, CNV analysis demonstrates copy-neutral loss of heterozygosity that extends from either 11q12.1 (CLL008) or 11q13.1 (CLL009) to the terminus of 11q. Both patients with UPD of 11q display homozygous mutation of the ATM gene. One patient (CLL008) has a point mutation in exon 58 of ATM (c.8161G>A (asp2721asn)) that likely involves the ATP binding site in the catalytic domain. One patient (CLL009) has a frameshift mutation in exon 24 of ATM (c.3238_3247del10bp/ins11bp; asp1080fs) that creates a premature stop signal at codon 1095, presumably resulting in a truncated protein. Conclusions: We report a new finding that ATM gene mutation occurs in CLL patients with UPD of 11q. Our study further expands observations reported by others concerning the role of ATM mutations in CLL. ATM mutations that we characterized include point mutations that may interfere with kinase activity and frameshift mutations that may result in a truncated ATM protein. Our sequence analysis supports a loss-of-function mechanism for ATM in a subgroup of high-risk, untreated CLL patients. The absence of detectable ATM mutations in the majority of CLL patients with 11q- may imply the existence of hidden ATM mutations not found by our targeted exon sequencing approach or epigenetic mechanisms that result in loss of gene expression. The finding that untreated CLL patients with UPD of 11q have homozygous ATM mutation supports a clonal selection hypothesis for identical alleles of mutated ATM in the absence of mutagenic chemotherapy. Selection of a CLL subclone with mutated ATM may confer a proliferative advantage through increased cell division and/or resistance to apoptosis following DNA damage. Disclosures: Zent: Genzyme: Research Funding; Genentech: Research Funding; Novartis: Research Funding; G.S.K.: Research Funding.
The Serum M-Spike and Transplant Outcome in Patients with Multiple Myeloma.
Hayman, Suzanne R. , Kumar, Shaji , Lacy, Martha Q. , Gastineau, Dennis A., Dingli, David , Pacheco, Jorge M. , Dispenzieri, Angela , Gastineau, Dennis A. , Gertz, Morie A.

Mayo Clinic

Blood | October 12, 2019 | Volume: 108 | Issue: 11 | Pages: 5441-5441

10.1182/blood.v108.11.5441.5441 Get It

Abstract Background: High dose therapy with autologous stem cell transplantation (HDT-ASCT) has prolonged survival in patients with multiple myeloma. Patients who achieve a complete response (CR) benefit the most from this form of therapy. Thus, achieving a CR is an important goal of therapy and it will be beneficial if the probability of achieving CR can be determined for any patient before transplant. Patients and Methods: A large cohort of patients with myeloma who received HDT-ASCT at Mayo Clinic Rochester was studied. The impact of various demographic, clinical and laboratory characteristics relating to the patients and their disease acquired were studied for their impact on response to HDT-ASCT, especially CR. Patients with a serum M-protein <0.1g/dL were excluded. Response definitions were as defined by established criteria. Survival analysis was performed according to the Kaplan-Meier method while univariate and multivariate analyses were performed with the proportional hazards method. We utilized knowledge of the rate of M-protein production by myeloma cells together with the clearance of the protein to estimate the pre-transplant disease burden. Results: We studied 224 patients with a median age of 56.5 years (32.6 – 71). Patients were transplanted a median of 8.7 months after diagnosis. Almost all patients had a response to HDT-ASCT and 78 (35%) achieved a CR. Those patients who achieved a CR had a longer time to progression (TTP) compared to those who did not achieve CR (Figure 1). The cohort was thus divided into two groups: patients who achieved CR and those that did not. The clinical and laboratory characteristics of the two groups were compared. Among the pre-transplant parameters tested, only the size of the serum M-spike was a predictor for CR (p<0.0001). A simple function that describes the probability of achieving CR based on the serum M-spike before HDT-ASCT is described. The estimated rate of tumor re-growth after HDT-ASCT in patients who obtain a CR and in patients who only get a partial response are presented. Conclusions: The pre-transplant disease burden in myeloma is the main determinant of response to HDT-ASCT. The individual probability of achieving CR can be estimated from simple clinical parameters providing a quantitative risk assessment prior to such a high-risk procedure. There is significant expansion of myeloma cells after HDT-ASCT. The design of clinical trials may benefit from knowledge of the kinetic aspects of the disease. Figure Figure
High-Dose Melphalan for AL Amyloidosis: The Importance of Case Selection to Improve Clinical Outcomes
Franke, Norman, Delgado, Diego , Stewart, Keith, Reece, Donna , Trudel, Suzanne , Chen, Christine , Kukreti, Vishal , Jimenez-Zepeda, Victor Hugo , Winter, Andrew, Mıkhael, Joseph

Mayo Clinic

Blood | October 12, 2019 | Volume: 116 | Issue: 21 | Pages: 2403-2403

10.1182/blood.v116.21.2403.2403 Get It

Abstract Abstract 2403 Immunoglobulin light chain amyloidosis (AL) is a monoclonal plasma cell disorder characterized by the accumulation of monoclonal light chain fragments that have undergone a conformational transformation and deposit as amyloid fibrils in different tissues. High-dose melphalan (HDM) with autologous hematopoietic stem-cell transplant (ASCT) is increasingly used to treat patients (pts) with AL Amyloidosis. However, transplant-related mortality (TRM) is high, ranging between 13% to 43%. The survival benefit of HDM has been attributed to a patient-selection bias. Recently, a randomized clinical trial by Jaccard A et al, showed longer survival in the group assigned to receive melphalan plus dexamethasone (Mel/Dex) than in the group assigned to receive HDM. The present is a retrospective study aiming to define which pts with AL are most likely to benefit from HDM. Patients and Methods We retrospectively reviewed the medical records of all the pts included in the Princess Margaret Hospital Amyloidosis Database who underwent ASCT from January 2004 to March 2010 to determine: a) TRM, b) Hematological response (HR) and Organ response (OR) and c) Overall survival (OS). We included transplanted pts who had received no more than two previous courses of any chemotherapy regimen who did not have concurrent myeloma, and who had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 2 or better. As part of the ASCT the stem cells were obtained from the peripheral blood with granulocyte colony-stimulating factor (G-CSF) alone (5 μ g/kg subcutaneously, twice daily). Pts then received HDM, 200 mg/m2 given intravenously on day 0, and stem cells were infused on day 1. The HDM was reduced to 140 mg/m2 for pts 65 years of age or older and for those with an important decrease of the ejection fraction, a calculated creatinine clearance of less than 30 ml per minute, or severe liver disease. HR and OR was assessed using 2004 Amyloidosis Consensus Response Criteria (Gertz, M et al, 2004). For statistical evaluation, HR was defined as observing complete or partial remission (CR or PR); stable disease (SD) or progression was considered as no HR. All statistical tests were 2-sided X2 t test and P values less than .05 were considered to be statistically significant. Results Seventy seven pts were evaluated with a median age of 56 years (33-74). Clinical characteristics are seen in Table 1. Only 18/77 pts (23%) received induction therapy: Dexamethasone alone n=9, Cyclophosphamide and Prednisone n=2, Mel/Dex n=4, VAD n=2 and Melphalan and Prednisone n=1. TRM observed was 12% mainly due to congestive heart failure and sepsis. Complete HR was achieved in 38 cases (49%) and OR was seen in 59%. Among the most common complications to ASCT, febrile neutropenia was reported in 67%, transient renal impairment in 10% and congestive heart failure in 3%. Median OS was significantly lower for patients with B-type natriuretic peptide (BNP) >300 pg/ml (17.7 vs 64.46 months) (p0.0004), Troponin I >0.07 ng/ml (19.25 vs 97.4 months) (p0.00001) and those who achieved a complete HR (115 vs 88 months) (p0.0345). Multivariate Cox regression analysis showed that BNP>300 pg/ml and Troponin I >0.07 ng/ml (normal <0.07) were the most important factors to predict OS for patients with AL who underwent ASCT (p0.0002 and 0.04 respectively). Conclusions Based on this study of 77 patients, clinical selection is the most important factor to better improve outcomes for HDM in AL. Patients with BNP>300 pg/ml and/or abnormal levels of Troponin I (>0.07) should not be considered eligible for transplants due to a high degree of mortality. Our series showed a CR rate of 49% which is higher than 33% reported by Palladini et al with Mel/Dex. Stringent case selection may be the most important factor in decreasing mortality rate associated to ASCT leading to better outcomes. Table 1. Clinical Characteristics of patients with AL Amyloidosis undergoing ASCT (at initial diagnosis) Clinical Characteristics N Median Range % Age (years) 77 57 33–74 Hemoglobin (g/L) 77 138 104–182 Creatinine (μ mol/L) 77 129 37–700 **BNP (pg/ml) 44 180 10–1670 ***BMPC (%)– 77 7 1–30 24 Hr Proteinuria (g/d) 77 5.5 0–24.9 Intraventricular Septal Distance (mm) 77 13 9–23 Kappa/lambda ratio 53 4.4 0.001–71.2 Kidney Involvement 71 Heart Involvement 52 Liver involvement 23 GI involvement 10 3 or more organs involved by AL 16 ** B-Type Natriuretic Peptide *** BMPC: Bone marrow plasma cells Disclosures: Stewart: Millennium: Consultancy; Celgene: Honoraria. Reece: Celgene: Honoraria, Research Funding. Chen: Celgene Corporation: Consultancy, Honoraria, Research Funding. Kukreti: Celgene: Honoraria.
Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples
Bhagwate, Aditya , Liu, Yuanhang , McDonough, Samantha J., Heinzen, Ethan P. , Frost, Marlene H., Cunningham, Julie M. , Winham, Stacey J. , Stallings‐Mann, Melody , Davila, Jaime , Vierkant, Robert A. , Hoskin, Tanya L. , Carter, Jodi M. , Radisky, Derek C. , Degnim, Amy C. , Wang, Chen

Mayo Clinic

No container title available | October 12, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.9892/v3 Get It

Abstract Background: Archived formalin fixed paraffin embedded (FFPE) samples are valuable clinical resources to examine clinically relevant morphology features and also to study genetic changes. However, DNA quality and quantity of FFPE samples are sub-optimal, and resulting NGS-based genetics variant detections are prone to false positives. Evaluations of wet-lab and bioinformatics approaches are needed to optimize variant detection from FFPE samples. Results: As a pilot study, we designed within-subject triplicate samples of DNA derived from paired FFPE and fresh frozen breast tissues to highlight FFPE-specific artifacts. For FFPE samples, we tested two FFPE DNA extraction methods to determine impact of wet-lab procedures on variant calling: QIAGEN QIAamp DNA Mini Kit ("QA"), and QIAGEN GeneRead DNA FFPE Kit ("QGR"). We also used negative-control (NA12891) and positive control samples (Horizon Discovery Reference Standard FFPE). All DNA sample libraries were prepared for NGS according to the QIAseq Human Breast Cancer Targeted DNA Panel protocol and sequenced on the HiSeq 4000. Variant calling and filtering were performed using QIAGEN Gene Globe Data Portal. Detailed variant concordance comparisons and mutational signature analysis were performed to investigate effects of FFPE samples compared to paired fresh frozen samples, along with different DNA extraction methods. In this study, we found that five times or more variants were called with FFPE samples, compared to their paired fresh-frozen tissue samples even after applying molecular barcoding error-correction and default bioinformatics filtering recommended by the vendor. We also found that QGR as an optimized FFPE-DNA extraction approach leads to much fewer discordant variants between paired fresh frozen and FFPE samples. Approximately 92 % of the uniquely called FFPE variants were of low allelic frequency range (<5%), and collectively shared a “C>T|G>A” mutational signature known to be representative of FFPE artifacts resulting from cytosine deamination. Based on control samples and FFPE-frozen replicates, we derived an effective filtering strategy with associated empirical false-discovery estimates. Conclusions: Through this study, we demonstrated feasibility of calling and filtering genetic variants from FFPE tissue samples using a combined strategy with molecular barcodes, optimized DNA extraction, and bioinformatics methods incorporating genomics context such as mutational signature and variant allelic frequency.
Comparable Outcomes with or without Routine Granulocyte Growth Factor Support Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT): A Single Center Experience.
Naina, Harris, Kumar, Shaji , Bitla, Shekhar, Greiner, Carl, Gastineau, Dennis A. , Winters, Jeffrey L. , Hogan, William J.

Mayo Clinic

Blood | October 12, 2019 | Volume: 114 | Issue: 22 | Pages: 1178-1178

10.1182/blood.v114.22.1178.1178 Get It

Abstract Abstract 1178 Poster Board I-200 Background: High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) has been shown to be of value in selected patients with malignant lymphoma and multiple myeloma (MM). Both granulocyte macrophage colony stimulating factor (GMCSF) and granulocyte colony stimulating factor (GCSF) are widely used following stem cell transplantation to support accelerated myeloid recovery and potentially shorten hospital stay. In the recent years, PBSCT is increasingly done in an ambulatory care setting and it is not clear if routine growth factor use has any potential benefit. We undertook this study to compare engraftment kinetics, incidence of febrile episodes, hospitalization duration and other outcomes among transplants done with or without growth factor support Patients and Methods: We included adult patients undergoing PBSCT for myeloma and lymphoma between May 2007 and June 2009 in an ambulatory care setting. Prior to April 2008 (Group-1) all patients received GMCSF 500 mcg/ day starting on day 6 routinely. Since April 2008, there was a shift in clinical practice and routine use of GMCSF was discontinued due to lack of clear evidence regarding benefit. Patients transplanted between April 2008 and June 2009 did not routinely receive GMCSF (Group-2). Typical conditioning regimen for lymphoma was BEAM (BCNU, Etoposide, Cytosine Arabinose, Melphalan) and for multiple myeloma was melphalan 200mg/m2. Patients' demographics details, indication for PBSCT, duration of neutropenic fever, hospital stay, and neutrophil and platelet engraftment were collected from electronic medical records. Neutrophil engraftment is defined as the first day of 2 consecutive days when ANC was > 0.5 × 109/L and platelet engraftment is defined as first of 7 consecutive days on which patient's unsupported platelet count was greater than 20× 109/L. Results: A total of 309 were included in this study, 126 (40%) patients in group-1 (69 with MM, 57 with lymphoma) and 183 (60%) in group-2 (100 with MM, 83 with lymphoma). In group-1, 73 (58%) and in group-2 130 (71%) were male patients. Median age was 59 (29-74) years in group 1 and 58 (24-76) years in group-2. Patients in group 1 received a median of 3.65 (1.1-8.7) versus 4.37 (1.1-9.54) CD34+ x106/kg in group 2 (P =0.005). Median time to neutrophil engraftment was 12 (95% CI 12, 12) for group-1 and 14 (95% CI; 13-14) for group-2 (Kaplan Meier analysis; log rank P < 0.0001). Median estimated time to platelet engraftment was 14 days (95% CI; 13, 15) for group 1 and 13 days (95% CI; 13-13) for group 2 (Kaplan Meier analysis; log rank P 0.007). In group-1 98 (78%) patients developed febrile episodes compared to 117(64%) in group-2 (P = 0.009). Median duration of fever was 2 days (range, 1-8) in group-1 compared to 1 day (range, 1-8) in group-2 (P = 0.0003). The median (range) duration of hospital stay was 7 (1-40) days for group-1 compared to 8 (2-56) days for group-2 (P=NS). There was no significant difference in mortality between these two groups. Conclusion: Routine use of granulocyte growth factors is associated with a shorter time to neutrophil engraftment, but associated with a delay in platelet engraftment. The longer time to neutrophil engraftment without growth factor use does not translate into any increase in frequency of febrile episodes. On the contrary, higher number of febrile days is seen with use of growth factors, likely explained on the basis of drug fever. No difference in the frequency of engraftment syndrome or treatment related mortality was seen. Disclosures: No relevant conflicts of interest to declare.
Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: a morphological basis of hypodense eosinophils
Peters, MS, Gleich, GJ, Dunnette, SL, Fukuda, Taku , Peters, M.S., Fukuda, T

Mayo Clinic

Blood | October 12, 2019 | Volume: 71 | Issue: 3 | Pages: 780-785

10.1182/blood.v71.3.780.bloodjournal713780 Get It

We investigated the ultrastructural characteristics and the granule major basic protein (MBP) content of hypodense eosinophils from patients with the hypereosinophilic syndrome who had at least 90% hypodense eosinophils in their peripheral blood and compared these cells to normodense eosinophils from normal persons. The hypodense cells (density less than 1.082) contained significantly less MBP than normodense (density greater than 1.082) eosinophils (P less than .001) as measured by radioimmunoassay (RIA). Electron microscopic examination demonstrated a mean of 25.0 +/- 4.4 (X +/- 1 SD) granules per hypodense cell, compared to 30.6 +/- 8.4 granules per cell in the normodense group (P less than .1). The most striking difference between the hypodense and normodense eosinophils was the small individual granule size (X = .14 +/- .05 v .26 +/- .05 micron 2, respectively, P less than .001), and the smaller total granule area (3.2 +/- 1.8 vs 7.7 +/- 3.1 micron 2, respectively, P less than .001). Because the cytoplasmic areas were similar in the two groups, the mean percent area of cytoplasm occupied by granules was significantly lower in the hypodense group (P less than .001). The finding of consistently smaller granules in the presence of equal or fewer granules per cell in the hypodense eosinophils may explain the lower MBP content and thus provide a morphologic basis for the low density of eosinophils in patients with the hypereosinophilic syndrome.
Fully Retargeted Oncolytic Measles Virus for Multiple Myeloma Therapy.
Hummel, Horst, Kuntz, Gaby, Greiner, Axel, Topp, Max S. , Nakamura, Takafumi , Greiner, Axel, Einsele, Hermann

Mayo Clinic

Blood | October 12, 2019 | Volume: 108 | Issue: 11 | Pages: 5474-5474

10.1182/blood.v108.11.5474.5474 Get It

Abstract Multiple Myeloma (MM) is a disseminated plasma cell malignancy with approximately 14,600 new cases diagnosed in the USA annually. Despite recent progress in current therapeutical options the median survival is 3 to 5 years and cure is extremely rare. Therefore the evaluation of new treatment modalities for MM is highly warranted. An attractive approach to treat Myeloma with a minimum of undesired side effects is the use of a tumour antigen specific for MM cells. Wue-1, a monoclonal antibody binds very selectively normal and malignant plasma cells (50 of 51 MM samples, 14 of 15 immunocytoma and 13 of 13 MALT type lymphomas with plasma cell differentiation were Wue-1 positive, normal tissue including hematopoietic cells were negative) and offers the possibility to define MM cells as targets. The tool for selective killing of MM cells recognized by Wue-1 monoclonal antibody is in this study the measles virus vaccine strain Edmonston B in an ablated variant (MV-Wue) which no longer binds the usual measles receptors CD46 and CD150 (SLAM) expressed on almost every human cell type displaying a single-chain antibody (scFv) derived from the monoclonal Wue-1-antibody which has been tethered to the C-terminus of the H protein to restrict and retarget its interaction to malignant plasma cells especially MM cells. In addition, MV-Wue encodes EGFP facilitating the read out of infected cells. To determine if the fully retargeted MV-Wue would be able to infect MM cell lines and primary MM cells selectively an array of infection assays were performed using the MM cell lines U266 as well as primary CD138 positive MM cells expressing the Wue-1 antigen as expected targets and CD138 negative cells and normal B cells as controls negative for Wue-1. In these experiments selective infections of the MM cell line and primary MM cells were observed whereas the control cells were not infected with MV-Wue. In all cell types GFP expression indicating replicative infection correlated with the expression of the Wue-1 antigen determined by FACS. Infection experiments performed in the presence of monoclonal Wue-1 antibody showed a decreased GFP expression of about 78% in CD138 positive MM cells demonstrating specificity of the infection by MV-Wue. These results indicate that the engineered virus can be a safe and potential curative oncolytic agent to face the main problem in Multiple Myeloma which is responsible for frequent relapses, the minimal residual disease (MRD).